In healthtech news:

🤰Tech companies added fertility features in response to anti-abortion laws. Tech companies picked an interesting time to start including women’s and reproductive health in their products. For years, they've sidestepped the issue: Apple didn’t include period tracking in its health app until 2015. Fitbit only added “Female health tracking” in 2018. For products that claim to help people understand their bodies, most spent years sidestepping the basic biology that affects half the population.  - The Verge

🥽 Can VR act as a digital therapeutic? The clinical potential of immersive virtual environments is not a recent discovery. Medical researchers and innovators have been building VR programs that deliver evidence-based treatments like exposure therapy, cognitive behavioral therapy, and pain management for years. But one of the primary features of virtual reality—so fundamental it is often overlooked—is its propensity for utterly commanding user attention. - FastCompany

📉 Telehealth Company Cerebral Cuts 20% of Workforce in Restructuring. Closely held Cerebral came under scrutiny in the spring after a Bloomberg News investigation into its prescribing practices of controlled medications, such as the ADHD treatment Adderall. The US Department of Justice is probing possible violations of the Controlled Substance Act and has not accused Cerebral of violating the law. The company previously announced layoffs in May. - Bloomberg 

Latest healthtech and biotech deals

The largest from last week:

🇺🇸 Recursion Pharma, an AI-powered drug designer, raised $150M in a Private placement. Additionaly, Recursion is ending the development of an investigational drug that could treat a rare inherited disease known as infantile GM2 gangliosidosis. The small molecule inhibitor of protein kinase C was set to enter phase 2 trials this spring, but Recursion delayed patient enrollment in March, setting the trial back by two years.

🇺🇸 Tempus, an AI- drug discovery, clinical trials and diagnostics platform, raised $275M in equity in debt. 

Other notable deals from around the globe:

🇩🇪 Anvajo, developer and manufacturer of point-of-care solutions for the diagnostic testing of liquids, raised €17.7M.

🇬🇧 Daye, plastic-free CBD-infused tampons, raised £10M in Series A. And it’s about to launch the world’s first tampon-based at-home vaginal microbiome screening kit and looks to expand to the US.

🇫🇷 SATELIA, a remote monitoring medical device for chronic diseases, raised €10M in Series A. It aims to propose solutions for a whole range of chronic diseases with the aim of avoiding hospitalizations and reducing the mortality rate.

Read up on all the latest health deals in Dealroom.co

Tip of the week

🏥 Top 100 Insurtech Startups to Watch

We’ve ranked the top insurtech startups globally to watch based on Dealroom Signal!

Insurtech startups raised a record $14.2 billion in 2021 and have raised $6.2B as of H2 2022. There are currently 62 insurance technology unicorns globally, or private companies with a valuation of over $1 billion.

Find out who the top 100 insurtech startups are to watch by clicking here. 👈

Job opportunities

🇳🇱 At Dealroom.co we are hiring a Data Quality Reviewer and an Intelligence Analyst Intern and 2 other roles.

Discover 65K+ jobs openings at healthtech and biotech startups. (login for full results)

Dive in

🌍 Healthtech’s decade: the MENA opportunity

👵🏼 The silver economy is in its prime

👩🏾‍⚕️ Healthtech Q2 2022

🩺 Medical education and training

Knowledge partners

Laura Rodriguez

Healthtech Specialist
Dealroom.co

Not a subscriber yet? 

This is Dealroom's weekly health newsletter.  Get more industry-specific intelligence on the evolving world of healthtech and biotech, emerging trends, and game-changing startups. Delivered on Fridays.